[1] Irvine K M, Ratnasekera I, Powell E E, et al. Causes and consequences of innate immune dysfunction in cirrhosis. Front Immunol, 2019, 10: 293. [2] Rockey D C. Infection-related mortality in patients with cirrhosis. Am J Med Sci, 2018, 355(2): 102-103. [3] Cannon M D, Martin P, Carrion A F. Bacterial infection in patients with cirrhosis: Don't get bugged to death. Dig Dis Sci, 2020, 65(1): 31-37. [4] Arvaniti V, D'amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology, 2010, 139(4): 1246-1256,e1261-1265. [5] Fernández J, Acevedo J, Wiest R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: Prevalence, characteristics and impact on prognosis. Gut, 2018, 67(10): 1870-180. [6] Fernández J, Prado V, Trebicka J, et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. J Hepatol, 2019, 70(3): 398-411. [7] Kamath P S, Wiesner R H, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology, 2001, 33(2): 464-470. [8] Pugh R N, Murray-lyon I M, Dawson J L, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg, 1973, 60(8): 646-649. [9] 徐小元,丁惠国,贾继东,等.肝硬化门静脉高压食管胃静脉曲张出血的防治指南.临床肝胆病杂志,2016,32(2):203-219. [10] 徐小元,丁惠国,李文刚, 等.肝硬化腹水及相关并发症的诊疗指南.实用肝脏病杂志,2018,21(1):21-31. [11] 徐小元,丁惠国,李文刚, 等.肝硬化肝性脑病诊疗指南.中国肝脏病杂志(电子版),2018,10(4):17-32. [12] Krowka M J, Fallon M B, Kawut S M, et al. International liver transplant society practice guidelines: Diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension. Transplantation, 2016, 100(7): 1440-1452. [13] 徐小元,丁惠国,李文刚, 等.肝硬化诊治指南.临床肝胆病杂志,2019,35(11):2408-2424,e2425. [14] 李春辉,吴安华.MDR、XDR、PDR多重耐药菌暂行标准定义-国际专家建议.中国感染控制杂志,2014,13(1):62-64. [15] Fernández J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study. Hepatology, 2012, 55(5): 1551-1561. [16] Fernández J, Navasa M, Gómez J, et al. Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology, 2002, 35(1): 140-148. [17] Lopes-secundo T M, Sevá-pereira T, Correa B R, et al. Serum sodium, model for end-stage liver disease, and a recent invasive procedure are risk factors for severe acute-on-chronic liver failure and death in cirrhotic patients hospitalized with bacterial infection. Eur J Gastroenterol Hepatol, 2018, 30(9): 1055-1059. [18] Kraja B, Sina M, Mone I, et al. Predictive value of the model of end-stage liver disease in cirrhotic patients with and without spontaneous bacterial peritonitis. Gastroenterol Res Pract, 2012, 2012: 539059. [19] Lingiah V A, Pyrsopoulos N T. Bacterial infections in cirrhotic patients in a tertiary care hospital. J Clin Transl Hepatol, 2021, 9(1): 32-39. [20] Assinger A. Platelets and infection-an emerging role of platelets in viral infection. Front Immunol, 2014, 5: 649. |